سويسرا - الإيطالية - Swissmedic (Swiss Agency for Therapeutic Products)

essential pharma switzerland gmbh - apraclonidinum - collirio (monodosen) - apraclonidinum 10 mg ut apraclonidini hydrochloridum 11.5 mg, natrii acetas trihydricus, natrii chloridum, acidum hydrochloridum aut natrii hydroxidum ad ph, aqua purificata q.s. ad solutionem pro 1 ml. - post-operatorio augendruckerhöhung - synthetika

إيطاليا - الإيطالية - Ministero della Salute

puressentiel italia srl -

إيطاليا - الإيطالية - AIFA (Agenzia Italiana del Farmaco)

essential pharma (m) ltd - etosuccimide - etosuccimide

إيطاليا - الإيطالية - AIFA (Agenzia Italiana del Farmaco)

essential pharma ltd - apraclonidina - apraclonidina

الاتحاد الأوروبي - الإيطالية - EMA (European Medicines Agency)

mylan pharmaceuticals limited - anagrelide cloridrato - trombocitemia, essenziale - agenti antineoplastici - anagrelide è indicato per la riduzione dei livelli elevati di piastrine nel a rischio thrombocythaemia essenziale (et) i pazienti che sono intolleranti al loro attuale terapia o la cui elevata conta delle piastrine non sono ridotti a un livello accettabile il loro attuale terapia. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.

الاتحاد الأوروبي - الإيطالية - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - radiofarmaci diagnostici - questo medicinale è solo per uso diagnostico. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy.  celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. nei pazienti adulti, per aiutare a differenziare probabile demenza con corpi di lewy dal morbo di alzheimer.  celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

إيطاليا - الإيطالية - AIFA (Agenzia Italiana del Farmaco)

farmapro s.r.l. - integratore alimentare a base di vitamine del gruppo b – e - vitamine e/o minerali - multivitamine/multiminerali

إيطاليا - الإيطالية - Ministero della Salute

navilyst medical inc. - kit per somministrazione - altri

إيطاليا - الإيطالية - AIFA (Agenzia Italiana del Farmaco)

a. nattermann & cie gmbh - terapia epatica - terapia epatica

إيطاليا - الإيطالية - Ministero della Salute

i.t. international trading s.r.l. - lenti oftalmiche organiche premontate con montature in plastica